The Acute Effects Of COPD Treatment On Cardiovascular Function

• Research type

  Research Study

• Full title

  A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Fuorate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults with Chronic Obstructive Pulmonary Disease (COPD)

• IRAS ID

  105492

• Contact name

  Neil Christopher Barnes

• Sponsor organisation

  GlaxoSmithKline

• Eudract number

  2012-000927-42

• ISRCTN Number

  xx

• Research summary

  There is an increased awareness that people with the lung condition chronic obstructive pulmonary disease (COPD) are at increased risk of developing heart problems. The risk is over and above what would be expected if you consider their shared risk factors such as smoking. The cause of this relationship is not fully understood but may partly related to the development of "air trapping", also known as hyper-inflation, caused by to an inability to empty the lungs properly when exhaling, which is often seen in COPD. Cardiac function and the size of the heart chambers has been shown to be affected by hyperinflation. We will therefore perform a trial to see if improvement in lung hyperinflation results in changes to the way the heart fills and functions, as assessed using advanced non-invasive cardiovascular imaging techniques.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  12/LO/0869

• Date of REC Opinion

  17 Jul 2012

• REC opinion

  Further Information Favourable Opinion